SEC ownership of PURPLE BIOTECH LTD.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001614744.

Comparable stake leader

INTRACOASTAL CAPITAL, LLC

Disclosed value leader

INTRACOASTAL CAPITAL, LLC

Comparable rows

4/23

Latest evidence

30 Jun 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
4 of 23
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
INTRACOASTAL CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
30 Jun 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001614744
Issuer location
Rehovot, Israel

Ownership snapshot

Top shareholders of PURPLE BIOTECH LTD. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
INTRACOASTAL CAPITAL, LLC
Disclosed value leader
INTRACOASTAL CAPITAL, LLC
Comparable rows
4/23
Latest evidence
30 Jun 2026
13D/G 3/4/5 13F Lead comparable stake: 10% 19 rows are not safely comparable across share classes. 13D/G row: INTRACOASTAL CAPITAL, LLC Showing 1-8 of 23 holder rows.

Quick read

INTRACOASTAL CAPITAL, LLC leads the comparable SEC ownership view at 10%.

4 of 23 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens INTRACOASTAL CAPITAL, LLC's linked filing trail.
Comparable ownership Top 4
INTRACOASTAL CAPITAL, LLC 10%
Lincoln Alternative Strategies LLC 9.9%
Orca Capital AG 4.9%
SUSQUEHANNA SECURITIES, LLC 1.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 23 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
INTRACOASTAL CAPITAL, LLC
13D/G
Mitchell P. Kopin
10%
Reported 13D/G · 31 Mar 2026
$124,305,955
282,513,535 shares
+$36,106,330 31 Mar 2026
Lincoln Alternative Strategies LLC
13D/G
9.9%
Reported 13D/G · 04 Sep 2025
$1,288,650
605,000 shares
$0 04 Sep 2025
Orca Capital AG
13D/G
4.9%
Reported 13D/G · 04 Sep 2025
$652,619
306,394 shares
$0 04 Sep 2025
SUSQUEHANNA SECURITIES, LLC
13D/G
G1 Execution Services, LLC
1.4%
Reported 13D/G · 30 Jun 2026
$45,104,400
26,532,000 shares
$0 30 Jun 2026
Gil Efron
3/4/5
Chief Executive Officer
—
denominator unverified
$10,355,625
15,750,000 shares
— 18 Mar 2026
Michael Schickler
3/4/5
Head of Clinical & Reg Affairs
—
denominator unverified
$6,084,815
9,254,472 shares
— 18 Mar 2026
Shai S. Lankry
3/4/5
Chief Financial Officer
—
denominator unverified
$2,334,125
3,550,000 shares
— 18 Mar 2026
Ido Agmon
3/4/5
Director
—
denominator unverified
$2,034,212
3,093,860 shares
— 18 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 24 Oct 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-7 of 7 reporting-owner rows connected to PURPLE BIOTECH LTD.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
7
Largest Forms 3/4/5 holder
Gil Efron
Net 12M change
$0
Latest report
18 Mar 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Gil Efron Chief Executive Officer $10,355,625 Mixed 18 Mar 2026
Michael Schickler Head of Clinical & Reg Affairs $6,084,815 Mixed 18 Mar 2026
Shai S. Lankry Chief Financial Officer $2,334,125 Mixed 18 Mar 2026
Ido Agmon Director $2,034,212 Mixed 18 Mar 2026
Robert E. Gagnon Director $1,531,250 Mixed 18 Mar 2026
Simcha Rock Director $1,411,384 Market 18 Mar 2026
Suzana Zilberberg Director $1,347,500 Market 18 Mar 2026

Recent insider transactions for PURPLE BIOTECH LTD.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Simcha Rock PPBT Ordinary Shares 0 3,207,690 18 Mar 2026 Direct
Suzana Zilberberg PPBT Ordinary Shares 0 3,062,500 18 Mar 2026 Direct
Ido Agmon PPBT Ordinary Shares 0 3,093,860 18 Mar 2026 Direct
Gil Efron PPBT Ordinary Shares 0 15,750,000 18 Mar 2026 Direct
Shai S. Lankry PPBT Ordinary Shares 0 3,550,000 18 Mar 2026 Direct
Michael Schickler PPBT Ordinary Shares 0 9,254,472 18 Mar 2026 Direct
Robert E. Gagnon PPBT Ordinary Shares 0 3,062,500 18 Mar 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .